Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 78

1.

Controlled delivery of naltrexone by an intraoral device: in vivo study on human subjects.

Paderni C, Campisi G, Schumacher A, Göttsche T, Giannola LI, De Caro V, Wolff A.

Int J Pharm. 2013 Aug 16;452(1-2):128-34. doi: 10.1016/j.ijpharm.2013.04.070. Epub 2013 May 2.

PMID:
23644347
2.

Bioavailability in vivo of naltrexone following transbuccal administration by an electronically-controlled intraoral device: a trial on pigs.

Campisi G, Giannola LI, Florena AM, De Caro V, Schumacher A, Göttsche T, Paderni C, Wolff A.

J Control Release. 2010 Aug 3;145(3):214-20. doi: 10.1016/j.jconrel.2010.04.027. Epub 2010 May 11.

PMID:
20438777
3.

Release of naltrexone on buccal mucosa: permeation studies, histological aspects and matrix system design.

Giannola LI, De Caro V, Giandalia G, Siragusa MG, Tripodo C, Florena AM, Campisi G.

Eur J Pharm Biopharm. 2007 Sep;67(2):425-33. Epub 2007 Mar 3.

PMID:
17451927
4.

New prospectives in the delivery of galantamine for elderly patients using the IntelliDrug intraoral device: in vivo animal studies.

Giannola LI, Paderni C, De Caro V, Florena AM, Wolff A, Campisi G.

Curr Pharm Des. 2010;16(6):653-9.

PMID:
20388075
6.

Single- and multiple-dose pharmacokinetics of long-acting injectable naltrexone.

Dunbar JL, Turncliff RZ, Dong Q, Silverman BL, Ehrich EW, Lasseter KC.

Alcohol Clin Exp Res. 2006 Mar;30(3):480-90.

PMID:
16499489
7.

Pharmacokinetics of long-acting naltrexone in subjects with mild to moderate hepatic impairment.

Turncliff RZ, Dunbar JL, Dong Q, Silverman BL, Ehrich EW, Dilzer SC, Lasseter KC.

J Clin Pharmacol. 2005 Nov;45(11):1259-67.

PMID:
16239359
8.

Diffusion of naltrexone across reconstituted human oral epithelium and histomorphological features.

Giannola LI, De Caro V, Giandalia G, Siragusa MG, Campisi G, Florena AM, Ciach T.

Eur J Pharm Biopharm. 2007 Feb;65(2):238-46. Epub 2006 Jul 26.

PMID:
16962298
9.

Comparative bioavailability study of a generic naltrexone tablet preparation.

Yuen KH, Peh KK, Billa N.

Drug Dev Ind Pharm. 1999 Mar;25(3):353-6.

PMID:
10071829
10.

Effects of alcohol on the pharmacokinetics of morphine sulfate and naltrexone hydrochloride extended release capsules.

Johnson FK, Ciric S, Boudriau S, Kisicki J, Stauffer J.

J Clin Pharmacol. 2012 May;52(5):747-56. doi: 10.1177/0091270011403740. Epub 2011 May 18.

PMID:
21593282
11.

Improving clinical outcomes in treating heroin dependence: randomized, controlled trial of oral or implant naltrexone.

Hulse GK, Morris N, Arnold-Reed D, Tait RJ.

Arch Gen Psychiatry. 2009 Oct;66(10):1108-15. doi: 10.1001/archgenpsychiatry.2009.130.

PMID:
19805701
12.

Preclinical study of an oral controlled release naltrexone complex in mice.

Alvarez-Fuentes J, Rojas-Corrales MO, Holgado MA, Caraballo I, Micó JA, Fernández-Arévalo M.

J Pharm Pharmacol. 2000 Jun;52(6):659-63.

PMID:
10875542
14.
16.

Sustained-release naltrexone for alcoholism treatment: a preliminary study.

Kranzler HR, Modesto-Lowe V, Nuwayser ES.

Alcohol Clin Exp Res. 1998 Aug;22(5):1074-9.

PMID:
9726277
17.

Achieving long-term continuous blood naltrexone and 6-beta-naltrexol coverage following sequential naltrexone implants.

Hulse GK, Arnold-Reed DE, O'Neil G, Chan CT, Hansson RC.

Addict Biol. 2004 Mar;9(1):67-72.

PMID:
15203441
18.

Risk factors for craving and relapse in heroin users treated with oral or implant naltrexone.

Hulse GK, Ngo HT, Tait RJ.

Biol Psychiatry. 2010 Aug 1;68(3):296-302. doi: 10.1016/j.biopsych.2010.04.003. Epub 2010 May 26.

PMID:
20537615
20.

Open-label pilot study of extended-release naltrexone to reduce drinking and driving among repeat offenders.

Lapham SC, McMillan GP.

J Addict Med. 2011 Sep;5(3):163-9. doi: 10.1097/ADM.0b013e3181eb3b89.

PMID:
21844831

Supplemental Content

Support Center